(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -9.8% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 57%.
Amarin's revenue in 2026 is $226,734,000.On average, 4 Wall Street analysts forecast AMRN's revenue for 2026 to be $74,150,869,681, with the lowest AMRN revenue forecast at $66,357,771,718, and the highest AMRN revenue forecast at $81,565,540,795. On average, 4 Wall Street analysts forecast AMRN's revenue for 2027 to be $73,044,698,892, with the lowest AMRN revenue forecast at $61,745,954,406, and the highest AMRN revenue forecast at $84,231,162,884.
In 2028, AMRN is forecast to generate $83,561,638,459 in revenue, with the lowest revenue forecast at $80,284,711,461 and the highest revenue forecast at $86,019,333,708.